Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Marathon Trading Investment Management LLC

Marathon Trading Investment Management LLC decreased its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 76.0% in the 2nd quarter, Holdings Channel.com reports. The fund owned 10,800 shares of the company’s stock after selling 34,200 shares during the period. Marathon Trading Investment Management LLC’s holdings in Fulcrum Therapeutics were worth $67,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in FULC. Vestal Point Capital LP bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $6,919,000. Opaleye Management Inc. bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $878,000. ADAR1 Capital Management LLC bought a new stake in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $4,302,000. Jane Street Group LLC lifted its holdings in shares of Fulcrum Therapeutics by 54.3% in the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after purchasing an additional 188,212 shares during the last quarter. Finally, Mass General Brigham Inc bought a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth approximately $1,939,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.44 on Thursday. Fulcrum Therapeutics, Inc. has a one year low of $2.87 and a one year high of $13.70. The stock’s fifty day moving average is $8.22 and its 200-day moving average is $8.12. The company has a market capitalization of $213.81 million, a PE ratio of -2.15 and a beta of 2.23.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The company had revenue of $80.00 million for the quarter, compared to the consensus estimate of $80.00 million. During the same quarter in the previous year, the business earned ($0.38) EPS. On average, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

FULC has been the topic of several recent research reports. Leerink Partnrs downgraded Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $22.00 to $3.00 in a report on Thursday, September 12th. HC Wainwright downgraded Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the stock from $17.00 to $4.00 in a report on Friday, September 13th. Cantor Fitzgerald downgraded Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.33.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.